ABSTRACT
Management of right ventricular outfl ow tract obstruction: Evolution to revolution dren die in early infancy and the remainder die at a mean age of 12.3 years. (5, 6) The advent of the Blalock shunt in the mid 1940s gave rise to the first palliative procedures in these children. This led to improved survival, but actuarial survival after 25 years in patients with all forms of palliative systemic to pulmonary artery shunts was in the region of 50% and quality of life was considered limited in 67% of these. (7) A new era was initiated when Lillehei performed the first successful ToF repair in 1954. (8) RVOTO following initial repair presented a significant challenge during this period. This gave rise to the widespread use of the trans annular patch (TAP) -up to 75% by the 1980s. (9, 10) These right ventricular outflow tracts dilated markedly over time and gave rise to pulmonary regurgitation (PR). PR was initially considered a benign condition and clinicians largely ignored it. However, after 3 -4 decades, unexpected episodes of cardiac deaths, dysrhythmias and right ventricular dysfunction were observed in these patients. Clinicians suddenly realised that PR is anything but an innocent condition.
In the current era emphasis has shifted to reparative surgery in early infancy and mortality has decreased too with operative mor-* Paediatric Cardiology, University Hospitals Leuven, Belgium # University of the Free State, South Africa
INTRODUCTION
Until recently, surgery has been the only definitive treatment for the management of right ventricular outflow tract obstruction (RVOTO). However, a considerable number of these patients will subsequently develop right heart and outflow tract dysfunction and will require pulmonary valve replacement (PVR). The introduction of percutaneous pulmonary valve implantation (PPVI) has opened up new avenues of treatment for this group of patients.
PPVI has been proven to be effective and safe with low complication rates. (1) (2) (3) A notable advantage is the avoidance of openheart surgery and cardiopulmonary bypass combined with short hospital stays.
In order to understand the complexities involved in these conditions, the management of tetralogy of Fallot (ToF) can be considered as a classical example of development of RVOTO management strategies. The historical progression of management needs closer inspection.
EVOLUTION OF TREATMENT FOR TETRALOGY OF FALLOT
Tetralogy of Fallot is the most common cyanotic congenital heart lesion accounting for 5 -6% of all congenital heart lesions. Summer 2014
Volume 11 • Number 1 talities as low as 2%. (11, 12) While the risk of surgery has declined, TAP is still necessary in some neonates. Current surgical strategies aim to minimise the use of the TAP, but early repair regularly requires aggressive outflow tract reconstruction in infants with significant RVOTO. (13) 
EFFECTS OF SIGNIFICANT PR
It is now well established that the haemodynamic substrate consisting of a dilating RVOT with resultant PR after reparative surgery in ToF patients is a major determinant of adverse outcomes.
Although clinically "asymptomatic", long-term follow-up studies show accumulating morbidity and mortality. Studies show that excess mortality persist for more than 30 years after surgery with mortality ratios ranging from 309% -714% and is clearly associated with the use of a TAP. (14) Sudden cardiac death has been reported in up to 6% of patients late after repair and has been estimated to occur at a rate of 0.2% per year. (14) (15) (16) (17) (18) Dysrhythmias are common in patients with PR and consist of atrial tachyarrhythmias in up to 30% and high grade ventricular tachycardias in 5 -10% of patients. (16, 19) Gatzoulis identified a prolonged QRS ≥180ms as a risk factor for ventricular tachycardia and sudden death. (20) Additional problems include cardiac failure and right heart dilation in up to 29% of patients with isolated PR. (21) Exercise intolerance with reduced oxygen uptake is also common in patients with dilated outflow tracts and PR. (19, 22) 
MANAGEMENT OF PR
Surgical pulmonary valve replacement has been the mainstay of treatment for patients with significant PR. Since their introduction in the early sixties, homografts have been the gold standard for PVR. (23) Several other bioprosthetic valves are used, but still have to be proven equivalent to homografts. (24) However, durability of homografts is not ideal and homograft degeneration after 10 years was observed in up to 46% of patients older than 10 years at implant; in younger patients degeneration was even more common: 65% after 5 years. (25, 26) Freedom from re-operation varies (see Table I ) with rates of 97% at 1 year to on average 52% -70% and 31% after 10 and 15 years, respectively. (24, (27) (28) (29) It should be pointed out that follow-up in most studies was not ideal and more frequent follow-up would likely have shortened the event free periods.
It has been projected that the average patient may thus require up to 5 operations during a normal lifespan, each with accumulative morbidity and reduction in life expectancy. As a result, clinicians tend to delay surgery as long as possible in order to reduce the number of surgeries. This wait and watch strategy has been criticised and studies have shown that right ventricular recovery after PVR may be compromised.
TIMING OF SURGERY
The ideal timing of PVR remains challenging and controversial. PVR was unlikely to result in "normalisation" of right ventricular end-diastolic volumes. (24) In a meta-analysis of adult and paediatric studies, Cheung observed that none of the studies reported complete normalisation of the RVEDV. (32) They also noticed that In summary, waiting for symptoms to appear before revalvulation is considered, will not lead to reversibility of right ventricular dysfunction. In a recent editorial Geva points out that our ability to prognosticate in these patients at present is poor and propose more liberal indications for PVR. (41) It is thus evident that clinicians should look at new strategies where long term event free right ventricular (RV) function -both mechanical and electrical-is the ultimate goal and not any degree of recuperation of size or function, that still can and probably will be associated with late premature dysfunction.
NEW STRATEGY OF PVR
Ideal treatment for patients with ToF or conditions with similar physiology should consist of PVR with a valved conduit with negligible procedural risk, perfect long-term function, absence of need for valve replacement and normal life expectancy both in quantity and quality. This is the strategy we have adopted for the management of atrial septal defects (ASD): at an early age when mild right ventricle dilation is observed, the unfavourable natural history is predictable and the procedure can be carried out with negligible risk combined with excellent long-term results. 
LIMITATIONS OF THIS STRATEGY
It should be noted that the abovementioned strategy is debat- 
